Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L7VC
|
|||
| Former ID |
DNCL002225
|
|||
| Drug Name |
GI-6207
|
|||
| Indication | Thyroid cancer [ICD-11: 2D10; ICD-10: C73; ICD-9: 193] | Phase 2 | [1], [2] | |
| Company |
GlobeImmune
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carcinoembryonic antigen CEA (CD66e) | Target Info | Modulator | [3] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of GlobeImmune. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.